Loading...
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
The introduction of high-efficacy therapies for relapsing–remitting multiple sclerosis has driven re-evaluation of treatment goals and benefit:risk considerations in treatment choice. In the alemtuzumab Phase II and III clinical trials, patients treated with alemtuzumab 12 mg versus subcutaneous int...
Na minha lista:
| Udgivet i: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5652900/ https://ncbi.nlm.nih.gov/pubmed/29081658 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S143509 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|